Biomarkers for Diagnosing and Treating Fetal Growth Restriction

Overview

Journal Curr Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2023 Nov 3

PMID 37921170

Authors

Mengyao Wu

Junyu He

Yetao Chen

Fangzhu Wan

Hongbo Tang

Chenghong Yin

Haibo He

Huifan Yu

Chengfu Yuan

Affiliations

Soon will be listed here.

Abstract

Fetal growth restriction (FGR), a common obstetric complication, significantly increases the risks of fetal intrauterine death and neonatal death, and fetuses with growth restriction are prone to cognitive retardation and various diseases in adulthood. The early determination of FGR risk is contentious in clinical research, and few indicators are available for the early prediction and diagnosis of FGR. This review focuses on the prediction and diagnosis of FGR, as well as the significance of biomarkers for FGR, such as those related to gene regulation, apoptosis, mitochondrial function, and inflammation. Although many of these biomarkers are still in the early stages of research, they are good predictors of the threats to fetal health and safety, and they provide new insights for the treatment of FGR.

References

Blencowe H, Krasevec J, de Onis M, Black R, An X, Stevens G . National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis. Lancet Glob Health. 2019; 7(7):e849-e860. PMC: 6560046. DOI: 10.1016/S2214-109X(18)30565-5. View

Sehgal A, Alexander B, Morrison J, South A . Fetal Growth Restriction and Hypertension in the Offspring: Mechanistic Links and Therapeutic Directions. J Pediatr. 2020; 224:115-123.e2. PMC: 8086836. DOI: 10.1016/j.jpeds.2020.05.028. View

Sharma A, Sah N, Kannan S, Kannan R . Targeted drug delivery for maternal and perinatal health: Challenges and opportunities. Adv Drug Deliv Rev. 2021; 177:113950. PMC: 8544131. DOI: 10.1016/j.addr.2021.113950. View

Damron D . Definition of fetal growth restriction. Am J Obstet Gynecol. 2020; 224(2):242. DOI: 10.1016/j.ajog.2020.09.031. View

Roeckner J, Pressman K, Odibo L, Duncan J, Odibo A . Outcome-based comparison of SMFM and ISUOG definitions of fetal growth restriction. Ultrasound Obstet Gynecol. 2021; 57(6):925-930. DOI: 10.1002/uog.23638. View

Aplin J, Myers J, Timms K, Westwood M . Tracking placental development in health and disease. Nat Rev Endocrinol. 2020; 16(9):479-494. DOI: 10.1038/s41574-020-0372-6. View

Schoots M, Bourgonje M, Bourgonje A, Prins J, van Hoorn E, Abdulle A . Oxidative stress biomarkers in fetal growth restriction with and without preeclampsia. Placenta. 2021; 115:87-96. DOI: 10.1016/j.placenta.2021.09.013. View

Bougea A . New markers in Parkinson's disease. Adv Clin Chem. 2020; 96:137-178. DOI: 10.1016/bs.acc.2019.12.001. View

Lees C, Romero R, Stampalija T, DallAsta A, DeVore G, Prefumo F . Clinical Opinion: The diagnosis and management of suspected fetal growth restriction: an evidence-based approach. Am J Obstet Gynecol. 2022; 226(3):366-378. PMC: 9125563. DOI: 10.1016/j.ajog.2021.11.1357. View

10.

Nowakowska B, Pankiewicz K, Nowacka U, Niemiec M, Kozlowski S, Issat T . Genetic Background of Fetal Growth Restriction. Int J Mol Sci. 2022; 23(1). PMC: 8744929. DOI: 10.3390/ijms23010036. View

11.

Zhang Q, Zhang C, Wang Y, Zhao J, Li H, Shen Q . Relationship of maternal obesity and vitamin D concentrations with fetal growth in early pregnancy. Eur J Nutr. 2021; 61(2):915-924. PMC: 8854300. DOI: 10.1007/s00394-021-02695-w. View

12.

Street M, Bernasconi S . Endocrine-Disrupting Chemicals in Human Fetal Growth. Int J Mol Sci. 2020; 21(4). PMC: 7073082. DOI: 10.3390/ijms21041430. View

13.

Kojima J, Ono M, Kuji N, Nishi H . Human Chorionic Villous Differentiation and Placental Development. Int J Mol Sci. 2022; 23(14). PMC: 9325306. DOI: 10.3390/ijms23148003. View

14.

Sheridan M, Fernando R, Gardner L, Hollinshead M, Burton G, Moffett A . Establishment and differentiation of long-term trophoblast organoid cultures from the human placenta. Nat Protoc. 2020; 15(10):3441-3463. DOI: 10.1038/s41596-020-0381-x. View

15.

Ortega M, Fraile-Martinez O, Garcia-Montero C, Saez M, Alvarez-Mon M, Torres-Carranza D . The Pivotal Role of the Placenta in Normal and Pathological Pregnancies: A Focus on Preeclampsia, Fetal Growth Restriction, and Maternal Chronic Venous Disease. Cells. 2022; 11(3). PMC: 8833914. DOI: 10.3390/cells11030568. View

16.

Sun C, Groom K, Oyston C, Chamley L, Clark A, James J . The placenta in fetal growth restriction: What is going wrong?. Placenta. 2020; 96:10-18. DOI: 10.1016/j.placenta.2020.05.003. View

17.

Groom K, David A . The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2017; 218(2S):S829-S840. DOI: 10.1016/j.ajog.2017.11.565. View

18.

Terstappen F, Richter A, Lely A, Hoebeek F, Elvan-Taspinar A, Bos A . Prenatal Use of Sildenafil in Fetal Growth Restriction and Its Effect on Neonatal Tissue Oxygenation-A Retrospective Analysis of Hemodynamic Data From Participants of the Dutch STRIDER Trial. Front Pediatr. 2020; 8:595693. PMC: 7744464. DOI: 10.3389/fped.2020.595693. View

19.

Karaman S, Paavonsalo S, Heinolainen K, Lackman M, Ranta A, Hemanthakumar K . Interplay of vascular endothelial growth factor receptors in organ-specific vessel maintenance. J Exp Med. 2022; 219(3). PMC: 8785977. DOI: 10.1084/jem.20210565. View

20.

Yan S, Hu J, Li J, Wang P, Wang Y, Wang Z . PRMT4 drives post-ischemic angiogenesis via YB1/VEGF signaling. J Mol Med (Berl). 2021; 99(7):993-1008. DOI: 10.1007/s00109-021-02067-1. View